Led by Tandem, small-cap medtechs pump up the value in 2018
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Convatec has a poor third quarter for the second year running
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.